Dose-dense chemotherapy is most effective for hormone-negative breast cancer, according to a review of clinical trials published in the Journal of the National Cancer Institute. The trials used doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) followed by paclitaxel. Dose-dense treatments for TNBC resulted in better overall and disease-free survival.
